- Home
- CRVO vs ACRV Comparison
CRVO vs ACRV Comparison
Compare CRVO & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRVO | ACRV |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 56.5M |
| IPO Year | 2011 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CRVO | ACRV |
|---|---|---|
| Price | $4.00 | $1.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $21.50 | $13.00 |
| AVG Volume (30 Days) | 79.7K | ★ 729.1K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,737,974.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.29 | N/A |
| 52 Week Low | $1.92 | $1.05 |
| 52 Week High | $16.50 | $5.75 |
Technical Indicators
Market Signals| Indicator | CRVO | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 32.65 | 41.92 |
| Support Level | N/A | $1.51 |
| Resistance Level | $5.44 | $2.47 |
| Average True Range (ATR) | 0.43 | 0.12 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 23.35 | 17.17 |
Price Performance
Historical ComparisonAbout CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.